PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.98%
R&D growth 5-10% suggests significant investment. Howard Marks would investigate if returns justify increased spending.
58.15%
G&A growth above 5% signals concerning overhead expansion. Seth Klarman would demand justification for increased costs.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.40%
Operating expenses growth above 10% signals concerning cost expansion. Seth Klarman would demand justification.
20.40%
Total costs growth above 5% signals concerning expansion. Seth Klarman would demand justification.
No Data
No Data available this quarter, please select a different quarter.
2.78%
D&A growth 0-5% reflects moderate asset expansion. Benjamin Graham would check if growth drives future value.
-20.82%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-20.40%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
97.30%
Other expenses growth above 30% signals concerning expansion. Seth Klarman would scrutinize unusual items.
-19.78%
Negative pre-tax income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.78%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
12.20%
EPS growth 12-15% shows strong earnings momentum. Peter Lynch would examine growth drivers.
12.20%
Diluted EPS growth 12-15% shows strong earnings power. Peter Lynch would examine growth drivers.
35.62%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
35.62%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.